FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:WHSC1L1-ADAM18

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: WHSC1L1-ADAM18
FusionPDB ID: 99193
FusionGDB2.0 ID: 99193
HgeneTgene
Gene symbol

WHSC1L1

ADAM18

Gene ID

54904

8749

Gene namenuclear receptor binding SET domain protein 3ADAM metallopeptidase domain 18
SynonymsKMT3F|KMT3G|WHISTLE|WHSC1L1|pp14328ADAM27|tMDCIII
Cytomap

8p11.23

8p11.22

Type of geneprotein-codingprotein-coding
Descriptionhistone-lysine N-methyltransferase NSD3WHSC1-like 1 isoform 9 with methyltransferase activity to lysineWolf-Hirschhorn syndrome candidate 1-like 1nuclear SET domain-containing protein 3protein whistledisintegrin and metalloproteinase domain-containing protein 18a disintegrin and metalloproteinase domain 18transmembrane metalloproteinase-like, disintegrin-like, and cysteine-rich protein III
Modification date2020031320200313
UniProtAcc.

Q9Y3Q7

Main function of 5'-partner protein: FUNCTION: Sperm surface membrane protein that may be involved in spermatogenesis and fertilization. This is a non catalytic metalloprotease-like protein (By similarity). {ECO:0000250}.
Ensembl transtripts involved in fusion geneENST idsENST00000317025, ENST00000433384, 
ENST00000527502, ENST00000316985, 
ENST00000525081, 
ENST00000523755, 
ENST00000520772, ENST00000541111, 
ENST00000379866, ENST00000265707, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score31 X 27 X 13=108818 X 8 X 6=384
# samples 469
** MAII scorelog2(46/10881*10)=-4.56403347974706
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(9/384*10)=-2.09310940439148
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: WHSC1L1 [Title/Abstract] AND ADAM18 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: WHSC1L1 [Title/Abstract] AND ADAM18 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)WHSC1L1(38137058)-ADAM18(39587417), # samples:2
Anticipated loss of major functional domain due to fusion event.WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
WHSC1L1-ADAM18 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneWHSC1L1

GO:0016571

histone methylation

16682010



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:38137058/chr8:39587417)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across WHSC1L1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ADAM18 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000317025WHSC1L1chr838137057-ENST00000265707ADAM18chr839587416+4444427851843481276
ENST00000433384WHSC1L1chr838137057-ENST00000265707ADAM18chr839587416+4270410449141741227
ENST00000527502WHSC1L1chr838137057-ENST00000265707ADAM18chr839587416+398538199238891265
ENST00000317025WHSC1L1chr838137058-ENST00000265707ADAM18chr839587417+4444427851843481276
ENST00000433384WHSC1L1chr838137058-ENST00000265707ADAM18chr839587417+4270410449141741227
ENST00000527502WHSC1L1chr838137058-ENST00000265707ADAM18chr839587417+398538199238891265

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000317025ENST00000265707WHSC1L1chr838137057-ADAM18chr839587416+0.0009716080.99902844
ENST00000433384ENST00000265707WHSC1L1chr838137057-ADAM18chr839587416+0.0009693820.9990306
ENST00000527502ENST00000265707WHSC1L1chr838137057-ADAM18chr839587416+0.0006523980.9993476
ENST00000317025ENST00000265707WHSC1L1chr838137058-ADAM18chr839587417+0.0009716080.99902844
ENST00000433384ENST00000265707WHSC1L1chr838137058-ADAM18chr839587417+0.0009693820.9990306
ENST00000527502ENST00000265707WHSC1L1chr838137058-ADAM18chr839587417+0.0006523980.9993476

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for WHSC1L1-ADAM18

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
WHSC1L1chr838137057ADAM18chr83958741638191242VRVGLFALCDIPAVIHPLYQKAMTWD
WHSC1L1chr838137057ADAM18chr83958741641041204VRVGLFALCDIPAVIHPLYQKAMTWD
WHSC1L1chr838137057ADAM18chr83958741642781253VRVGLFALCDIPAVIHPLYQKAMTWD
WHSC1L1chr838137058ADAM18chr83958741738191242VRVGLFALCDIPAVIHPLYQKAMTWD
WHSC1L1chr838137058ADAM18chr83958741741041204VRVGLFALCDIPAVIHPLYQKAMTWD
WHSC1L1chr838137058ADAM18chr83958741742781253VRVGLFALCDIPAVIHPLYQKAMTWD

Top

Potential FusionNeoAntigen Information of WHSC1L1-ADAM18 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
WHSC1L1-ADAM18_38137057_39587416.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:03IPAVIHPL0.99660.78851018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:02IPAVIHPL0.97790.87041018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:04IPAVIHPL0.97790.87041018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:01IPAVIHPLY0.99920.63781019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:08IPAVIHPLY0.99690.53731019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B15:02IPAVIHPLY0.99350.72411019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:22ALCDIPAVI0.99230.5984615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:30ALCDIPAVI0.9920.6611615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:67ALCDIPAVI0.9920.6611615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:60ALCDIPAVI0.9920.6303615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:24ALCDIPAVI0.9920.6611615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:11ALCDIPAVI0.99140.6967615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:21FALCDIPAV0.9910.8685514
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:27ALCDIPAVI0.99030.5978615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A30:08AVIHPLYQK0.99020.74611221
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:16ALCDIPAVI0.98920.6098615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:13ALCDIPAVI0.98840.6636615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B51:02FALCDIPAV0.98650.8613514
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:38ALCDIPAVI0.98070.6278615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:19ALCDIPAVI0.96250.506615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:03IPAVIHPLY0.95230.68821019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:35ALCDIPAVI0.92450.68615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:29ALCDIPAVI0.83830.6654615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:20ALCDIPAVI0.83330.6635615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:04IPAVIHPLY0.70040.73621019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:02IPAVIHPLY0.70040.73621019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:01IPAVIHPLY0.68290.68581019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B13:02ALCDIPAVI0.17760.8825615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:11GLFALCDIPAV0.99410.6514314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:24GLFALCDIPAV0.9940.6131314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:30GLFALCDIPAV0.9940.6131314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:67GLFALCDIPAV0.9940.6131314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:60GLFALCDIPAV0.99390.6583314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:16GLFALCDIPAV0.99250.6181314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:35GLFALCDIPAV0.93580.6229314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:20GLFALCDIPAV0.91360.6229314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:29GLFALCDIPAV0.90670.6177314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:12IPAVIHPL0.97790.87041018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B39:10IPAVIHPL0.89930.81171018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B15:31IPAVIHPLY0.9990.59171019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B15:21IPAVIHPLY0.99360.65731019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:01ALCDIPAVI0.9920.6611615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:12IPAVIHPLY0.70040.73621019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-C01:30DIPAVIHPL0.4740.9501918
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-C01:17DIPAVIHPL0.05690.921918
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:01GLFALCDIPAV0.9940.6131314
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:13IPAVIHPL0.99650.80461018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:30IPAVIHPL0.98280.57981018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:17IPAVIHPL0.98280.57981018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:09IPAVIHPL0.97790.87041018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B67:01IPAVIHPL0.94250.58411018
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:77IPAVIHPLY0.99920.63781019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:23IPAVIHPLY0.99910.62591019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:20IPAVIHPLY0.9990.71771019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:24IPAVIHPLY0.99830.6361019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:11IPAVIHPLY0.99270.65121019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:03ALCDIPAVI0.99140.6956615
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:14FALCDIPAV0.99110.8503514
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A02:06FALCDIPAV0.9910.8685514
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A30:01AVIHPLYQK0.9870.80241221
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A25:01DIPAVIHPL0.97630.8886918
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:04IPAVIHPLY0.93580.71891019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:11IPAVIHPLY0.88570.58511019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A69:01DIPAVIHPL0.85540.6454918
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B51:09FALCDIPAV0.81160.8213514
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:07IPAVIHPLY0.7390.5991019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:09IPAVIHPLY0.70040.73621019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:06IPAVIHPLY0.69370.6791019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:03IPAVIHPLY0.68510.66971019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:05IPAVIHPLY0.68290.68581019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:08IPAVIHPLY0.67890.54831019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B15:08IPAVIHPLY0.52330.57861019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B15:11IPAVIHPLY0.50760.58671019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:43IPAVIHPLY0.47590.57731019
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-C01:02DIPAVIHPL0.03770.9198918
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-C01:03DIPAVIHPL0.02990.909918
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-A25:01DIPAVIHPLY0.99220.7528919
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B35:24DIPAVIHPLY0.98030.6415919
WHSC1L1-ADAM18chr838137057chr8395874164278HLA-B18:07DIPAVIHPLY0.69280.6338919

Top

Potential FusionNeoAntigen Information of WHSC1L1-ADAM18 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
WHSC1L1-ADAM18_38137057_39587416.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1201PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1201IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1201DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1203PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1203IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1203DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1204PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1205PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1205IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1205DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1206PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1206IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1206DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1207PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1207IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1207DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1208PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1208IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1208DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1209PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1210PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1210IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1210DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1211PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1211IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1211DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1212PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1212IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1212DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1213PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1213IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1213DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1214PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1214IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1214DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1215PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1215IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1215DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1216PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1217PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1217IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1217DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1218PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1218IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1218DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1219PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1219IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1219DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1220PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1220IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1220DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1221PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1221IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1221DIPAVIHPLYQKAMT924
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1223PAVIHPLYQKAMTWD1126
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1223IPAVIHPLYQKAMTW1025
WHSC1L1-ADAM18chr838137057chr8395874164278DRB1-1223DIPAVIHPLYQKAMT924

Top

Fusion breakpoint peptide structures of WHSC1L1-ADAM18

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
342ALCDIPAVIHPLYQWHSC1L1ADAM18chr838137057chr8395874164278

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of WHSC1L1-ADAM18

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN342ALCDIPAVIHPLYQ-7.15543-7.26883
HLA-B14:023BVN342ALCDIPAVIHPLYQ-4.77435-5.80965
HLA-B52:013W39342ALCDIPAVIHPLYQ-6.80875-6.92215
HLA-B52:013W39342ALCDIPAVIHPLYQ-4.20386-5.23916
HLA-A11:014UQ2342ALCDIPAVIHPLYQ-7.5194-8.5547
HLA-A11:014UQ2342ALCDIPAVIHPLYQ-6.9601-7.0735
HLA-A24:025HGA342ALCDIPAVIHPLYQ-7.52403-7.63743
HLA-A24:025HGA342ALCDIPAVIHPLYQ-5.82433-6.85963
HLA-B27:056PYJ342ALCDIPAVIHPLYQ-3.28285-4.31815
HLA-B44:053DX8342ALCDIPAVIHPLYQ-5.91172-6.94702
HLA-B44:053DX8342ALCDIPAVIHPLYQ-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of WHSC1L1-ADAM18

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
WHSC1L1-ADAM18chr838137057chr8395874161018IPAVIHPLTTCCTGCAGTAATTCATCCGTTGT
WHSC1L1-ADAM18chr838137057chr8395874161019IPAVIHPLYTTCCTGCAGTAATTCATCCGTTGTATC
WHSC1L1-ADAM18chr838137057chr8395874161221AVIHPLYQKCAGTAATTCATCCGTTGTATCAGAAAG
WHSC1L1-ADAM18chr838137057chr839587416314GLFALCDIPAVGACTATTTGCTCTCTGTGATATTCCTGCAGTAA
WHSC1L1-ADAM18chr838137057chr839587416514FALCDIPAVTTGCTCTCTGTGATATTCCTGCAGTAA
WHSC1L1-ADAM18chr838137057chr839587416615ALCDIPAVICTCTCTGTGATATTCCTGCAGTAATTC
WHSC1L1-ADAM18chr838137057chr839587416918DIPAVIHPLATATTCCTGCAGTAATTCATCCGTTGT
WHSC1L1-ADAM18chr838137057chr839587416919DIPAVIHPLYATATTCCTGCAGTAATTCATCCGTTGTATC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
WHSC1L1-ADAM18chr838137057chr8395874161025IPAVIHPLYQKAMTWTTCCTGCAGTAATTCATCCGTTGTATCAGAAAGCGATGACGTGGG
WHSC1L1-ADAM18chr838137057chr8395874161126PAVIHPLYQKAMTWDCTGCAGTAATTCATCCGTTGTATCAGAAAGCGATGACGTGGGACA
WHSC1L1-ADAM18chr838137057chr839587416924DIPAVIHPLYQKAMTATATTCCTGCAGTAATTCATCCGTTGTATCAGAAAGCGATGACGT

Top

Information of the samples that have these potential fusion neoantigens of WHSC1L1-ADAM18

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
COADWHSC1L1-ADAM18chr838137057ENST00000317025chr839587416ENST00000265707TCGA-D5-6926

Top

Potential target of CAR-T therapy development for WHSC1L1-ADAM18

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneADAM18chr8:38137057chr8:39587416ENST0000052077206688_7080183.0TransmembraneHelical
TgeneADAM18chr8:38137058chr8:39587417ENST0000052077206688_7080183.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to WHSC1L1-ADAM18

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to WHSC1L1-ADAM18

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource